- Home
- AKA vs INBX Comparison
AKA vs INBX Comparison
Compare AKA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | INBX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 430.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AKA | INBX |
|---|---|---|
| Price | $11.37 | $79.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 242.1K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $595,281,000.00 | $1,400,000.00 |
| Revenue This Year | $5.57 | $563.00 |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $7.00 | $10.81 |
| 52 Week High | $20.56 | $94.57 |
Technical Indicators
Market Signals| Indicator | AKA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 48.17 |
| Support Level | $10.25 | $76.22 |
| Resistance Level | $11.58 | $94.57 |
| Average True Range (ATR) | 0.58 | 6.98 |
| MACD | 0.03 | -1.37 |
| Stochastic Oscillator | 62.91 | 21.88 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.